Digital Pathology Market

Digital Pathology Market by Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals) & Region - Global Forecast to 2026

Report Code: HIT 2608 Mar, 2022, by marketsandmarkets.com

Updated on : April 12, 2023

The global digital pathology market in terms of revenue was estimated to be worth $736 million in 2021 and is poised to reach $1,371 million by 2026, growing at a CAGR of 13.2% from 2022 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth in this market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, the rising incidence of cancer, and the growing applications of digital pathology in drug development and companion diagnostics. Moreover, the introduction of affordable scanners for private pathology practices has opened greater opportunities for market growth.

Digital Pathology Market

To know about the assumptions considered for the study, Request for Free Sample Report

Digital Pathology Market Dynamics

Driver: Increasing adoption of digital pathology to enhance lab efficiency

The increasing adoption of digital pathology is driving the global digital pathology market. Digital pathology is used in diagnosis and treatment of diseases. It has the potential to revolutionize the diagnosis of diseases by providing accurate, efficient, and cost-effective solutions. Digital pathology solutions are used to store, manage, and analyze digital images of tissue and organ slides. This helps in quick diagnosis and reduces turnaround time. Moreover, digital pathology solutions can be linked to electronic medical records, which helps in seamless sharing of information between healthcare providers. This, in turn, helps in improving clinical outcomes and patient care. The increasing demand for enhanced lab efficiency is also driving the growth of the global digital pathology market.

Opportunity: Introduction of affordable scanners for private pathology practices

The introduction of affordable scanners for private pathology practices presents an opportunity for the digital pathology market. With the ability to scan slides at a lower cost, private practices are able to benefit from the advantages of digital pathology, such as increased accuracy and efficiency, while avoiding the high costs associated with traditional hardware and software. Additionally, these affordable scanners can help bridge the gap between larger pathology labs and smaller private practices, allowing them to access the same technology and benefit from the same advantages even with limited resources. This can help to improve diagnostic accuracy, reduce costs, and improve patient outcomes.

Restraint: High cost of digital pathology systems

Digital pathology systems are expensive and require significant capital investment. The cost of the hardware, software and services associated with the system can be quite high. This is a major factor that is likely to restrain the growth of the digital pathology market. The cost of a digital pathology system can range from USD 50,000 to several million dollars depending on the features and capabilities of the system. This is a major factor that is likely to restrain the growth of the digital pathology market.

Challenge: Shortage of trained pathologists

The current shortage of trained pathologists poses a challenge to the digital pathology market. This is because digital pathology requires skilled professionals to interpret the digital images of tissue samples which are created using digital imaging and image analysis technologies. The lack of trained professionals raises concerns about the accuracy of digital pathology results and the quality of care provided. Additionally, it also limits the ability of digital pathology to be utilized in clinical settings. To address this challenge, initiatives such as training programs and collaborations between academic institutions and private companies are being implemented. This will help to ensure that qualified pathologists are available to interpret digital pathology images. Additionally, digital pathology platforms are also being developed to reduce the need for expertise in order for users to accurately interpret the images.

The scanners segment accounted for the largest share of the digital pathology market.

Digital pathology scanners create whole-slide images (WSI) from glass slides. Converting the images into digital form helps view, analyse, manage, share, and store them easily and efficiently. The scanner identifies certain key points on the tissue and scans it piece by piece. Scanners capture several image resolutions, compress them, and store them in an image file. Along with these benefits, the large share of the scanners segment can be attributed to the high price of scanners and the increasing adoption of digital pathology solutions.

The human pathology segment accounted for the largest share of the digital pathology market.

Human pathology is the study and diagnosis of diseases by examining organs, tissues, cells, and bodily fluids. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to understanding human diseases. The human pathology segment accounted for the largest share of this market. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories.

The drug discovery segment accounted for the largest share of the digital pathology market.

Pharmaceutical, biopharmaceutical, and medical device companies invest heavily in developing novel drugs and devices, with most of the expenditure concentrated on phase III and the preclinical stages of drug development. Growth in R&D expenditure, fuelled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process, is one of the major factors propelling the drug discovery market.

The pharmaceutical & biotechnology companies, segment accounted for the largest share of the digital pathology market.

The pharmaceutical and biotechnology companies held the largest share of this market. The large share of this segment can be attributed to the increasing use of digital pathology for drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualised medicine.

Digital Pathology Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America is projected to witness the highest growth rate in the digital pathology market during the forecast period.

North America accounted for the largest share of the market. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favourable reimbursement policies, and the implementation of favourable initiatives by the governments in the US and Canada are major factors driving the growth of the global market in North America

The major players in the global Digital Pathology market are Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (US), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Inspirata, Inc. (US), PathAI (US), Proscia Inc. (US), Kanteron Systems (Spain), Mikroscan Technologies (US), Motic (US), and Paige (US).

Digital Pathology Market Report Scope

Report Metric

Details

Market Revenue in 2021

$736 million

Projected Revenue by 2026

$1,371 million

Revenue Rate

Poised to grow at a CAGR of 13.2%

Market Driver

Increasing adoption of digital pathology to enhance lab efficiency

Market Opportunity

Introduction of affordable scanners for private pathology practices

This research report categorizes the digital pathology market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Scanners
    • Brightfield
    • Other Scanners
  • Software
    • Integrated Software
    • Standalone Software
      • Information Management Software
      • Image Analysis Software
  • Storage Systems

By Type

  • Human Pathology
  • Veterinary Pathology

By Application

  • Drug Discovery
  • Disease Diagnosis
  • Training & Education

By End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals and Reference Laboratories
  • Academic & Research Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • UK
    • Sweden
    • Denmark
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In September 2021, Visiopharm (Denmark) and Agilent Technologies, Inc. (US) collaborated to co-market Visiopharm’s portfolio of CE-IVD marked AI-driven Precision Pathology software and Agilent’s automated pathology staining solutions portfolio.
  • In August 2021, Sectra AB (Sweden) and University Medical Center Utrecht (Netherlands) signed an agreement under which UMC uses Sectra’s pathology module for effective multidisciplinary discussions among pathologists and radiologists.
  • In May 2021, Sectra AB (Sweden) and Institut Curie (France) signed an agreement which allows the digitization of pathology at Institut Curie. The pathologists in Institut Curie can access cases, digital tools, and AI applications through the Sectra pathology solution.
  • In April 2021, Leica Biosystems (US) and Paige.AI, Inc. (US) partnered for Paige’s AI-enabled research software for tumor detection, grading, and quantification to Leica Biosystems digital pathology platform in countries throughout North America and Europe.
  • In August 2020, Leica Biosystems (US) and Bio-Techne Corporation (US) partnered to automate RNAscope COVID-19 probes on Leica’s BOND RX platform for research use. This helps reduce manual labor and turnaround time.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 35)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 DIGITAL PATHOLOGY MARKET
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from primary experts
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                    2.1.2.3 Breakdown of primary sources
                               FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY CATEGORY, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 7 ILLUSTRATIVE EXAMPLE OF LEICA BIOSYSTEMS (SUBSIDIARY OF DANAHER CORPORATION)
           FIGURE 8 SUPPLY-SIDE ANALYSIS: GLOBAL MARKET (2020)
           FIGURE 9 BOTTOM-UP APPROACH
           FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 11 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE DIGITAL PATHOLOGY MARKET (2021–2026)
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 12 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT
           TABLE 1 RISK ASSESSMENT: GLOBAL MARKET
    2.7 MARKET LIMITATIONS
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 52)
    FIGURE 13 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 GLOBAL MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 GLOBAL MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 17 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 56)
    4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
           FIGURE 18 RISING PREVALENCE OF CANCER IS A KEY FACTOR DRIVING MARKET GROWTH
    4.2 NORTH AMERICA: MARKET, BY END USER & COUNTRY (2020)
           FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
    4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 20 MARKET IN THE UK TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
    4.4 REGIONAL MIX: GLOBAL MARKET (2021–2026)
           FIGURE 21 NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)
    4.5 GLOBAL MARKET: DEVELOPING VS. DEVELOPED MARKETS
           FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 60)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 23 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing adoption of digital pathology to enhance lab efficiency
                    5.2.1.2 Rising incidence of cancer
                               TABLE 2 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
                    5.2.1.3 Growing applications of digital pathology in drug development and companion diagnostics
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of digital pathology systems
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Introduction of affordable scanners for private pathology practices
                    5.2.3.2 Growing demand for personalized medicine
                               TABLE 3 US: GROWTH IN THE NUMBER OF PERSONALIZED MEDICINES (2008–2020)
                    5.2.3.3 High growth opportunities in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of trained pathologists
                               TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020
    5.3 COVID-19 IMPACT ANALYSIS
           5.3.1 IMPACT OF COVID-19 ON THE GLOBAL MARKET
                    FIGURE 24 IMPACT OF COVID-19 ON THE GLOBAL MARKET
    5.4 ECOSYSTEM MARKET MAP
           FIGURE 25 GLOBAL MARKET: ECOSYSTEM MARKET MAP
    5.5 TRENDS IN AVERAGE SELLING PRICE
           FIGURE 26 GLOBAL MARKET: AVERAGE REGIONAL PRICES OF DIGITAL PATHOLOGY SCANNERS
    5.6 IMPACT OF THE NEW IVD REGULATION ON DIFFERENT MARKETS
           FIGURE 27 TIMELINE AND TRANSITION TO NEW MDR AND IVDR
           5.6.1 IMPACT ON CLINICAL LAB SERVICES
           5.6.2 IMPACT ON IVD
           5.6.3 IMPACT ON DIGITAL PATHOLOGY
    5.7 TECHNOLOGY ANALYSIS
           5.7.1 ARTIFICIAL INTELLIGENCE (AI) IN DIGITAL PATHOLOGY
                    TABLE 5 DIGITAL PATHOLOGY AI MARKET, BY REGION, 2019–2026 (USD MILLION)
    5.8 PATENT ANALYSIS
           5.8.1 METHODOLOGY
           5.8.2 PUBLICATION TRENDS
                    FIGURE 28 PUBLICATION TRENDS, 2015–2021
           5.8.3 JURISDICTION ANALYSIS
                    FIGURE 29 JURISDICTION ANALYSIS, 2015–2021
           5.8.4 TOP APPLICANTS
                    FIGURE 30 TOP APPLICANTS, 2015–2021

6 DIGITAL PATHOLOGY MARKET, BY PRODUCT (Page No. - 75)
    6.1 INTRODUCTION
           TABLE 6 GLOBAL MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 SCANNERS
           6.2.1 SCANNERS ACCOUNTED FOR THE LARGEST SHARE OF THE DIGITAL PATHOLOGY PRODUCTS MARKET IN 2020
                    TABLE 7 SCANNING MAGNIFICATION AND APPLICATIONS
                    TABLE 8 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS
                    TABLE 9 DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 10 DIGITAL PATHOLOGY SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 11 DIGITAL PATHOLOGY SCANNERS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 12 DIGITAL PATHOLOGY SCANNERS MARKET, BY REGION, 2019–2026 (UNITS)
                    6.2.1.1 Brightfield scanners
                               TABLE 13 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS
                               TABLE 14 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.2 Other scanners
                               TABLE 15 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS
                               TABLE 16 OTHER SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 SOFTWARE
           TABLE 17 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS
           TABLE 18 DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 19 DIGITAL PATHOLOGY SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.1 INTEGRATED SOFTWARE
                    6.3.1.1 Integrated software segment to dominate the market during the forecast period
                               TABLE 20 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS
                               TABLE 21 INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.2 STANDALONE SOFTWARE
                    TABLE 22 STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 23 STANDALONE SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.1 Information management software
                               6.3.2.1.1 Information management software enables comprehensive integration with any institute’s information systems
                                            TABLE 24 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS
                                            TABLE 25 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.2 Image analysis software
                               6.3.2.2.1 Image analysis software provides easy-to-use solutions for the quantitative evaluation of brightfield slides
                                            TABLE 26 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS
                                            TABLE 27 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.4 STORAGE SYSTEMS
           6.4.1 REQUIREMENT FOR THE SAFE AND RELIABLE STORAGE OF HIGH-QUALITY IMAGES TO ENSURE MARKET GROWTH
                    TABLE 28 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS
                    TABLE 29 STORAGE SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 DIGITAL PATHOLOGY MARKET, BY TYPE (Page No. - 93)
    7.1 INTRODUCTION
           TABLE 30 GLOBAL MARKET, BY TYPE, 2019–2026 (USD MILLION)
    7.2 HUMAN PATHOLOGY
           7.2.1 THE COVID-19 PANDEMIC HAS LED TO AN INCREASING DEMAND FOR DIGITAL PATHOLOGY SOLUTIONS
                    TABLE 31 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 VETERINARY PATHOLOGY
           7.3.1 VETERINARY DIGITAL PATHOLOGY REDUCES THE TURNAROUND TIME FOR ANIMAL DISEASE DIAGNOSIS-KEY FACTOR DRIVING THE MARKET GROWTH
                    TABLE 32 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 DIGITAL PATHOLOGY MARKET, BY APPLICATION (Page No. - 97)
    8.1 INTRODUCTION
           TABLE 33 GLOBAL MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 34 PRODUCT CROSSED MAPPING FOR DIFFERENT APPLICATIONS
           TABLE 35 DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 36 DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
    8.2 DRUG DISCOVERY
           8.2.1 INCREASING R&D SPENDING TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 37 APPLICATIONS OF DIGITAL PATHOLOGY IN DRUG DISCOVERY
                    TABLE 38 GLOBAL MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 39 DIGITAL PATHOLOGY SCANNERS MARKET FOR DRUG DISCOVERY, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 40 DIGITAL PATHOLOGY SCANNERS MARKET FOR DRUG DISCOVERY, BY REGION, 2019–2026 (UNITS)
    8.3 DISEASE DIAGNOSIS
           8.3.1 USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIGITAL PATHOLOGY SOLUTIONS FOR DIAGNOSTIC PURPOSES TO DRIVE MARKET GROWTH
                    TABLE 41 GLOBAL MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 42 DIGITAL PATHOLOGY SCANNERS MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 43 DIGITAL PATHOLOGY SCANNERS MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2019–2026 (UNITS)
    8.4 TRAINING & EDUCATION
           8.4.1 DIGITAL PATHOLOGY CAN IMPROVE EDUCATION & TRAINING PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES
                    TABLE 44 GLOBAL MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 45 DIGITAL PATHOLOGY SCANNERS MARKET FOR TRAINING & EDUCATION, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 46 DIGITAL PATHOLOGY SCANNERS MARKET FOR TRAINING & EDUCATION, BY REGION, 2019–2026 (UNITS)

9 DIGITAL PATHOLOGY MARKET, BY END USER (Page No. - 106)
    9.1 INTRODUCTION
           TABLE 47 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 48 PRODUCT CROSSED MAPPING FOR DIFFERENT END USERS
           TABLE 49 DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 50 DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST & FASTEST-GROWING END USERS OF THE GLOBAL MARKET
                    TABLE 51 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 52 DIGITAL PATHOLOGY SCANNERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 53 DIGITAL PATHOLOGY SCANNERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (UNITS)
    9.3 HOSPITALS & REFERENCE LABORATORIES
           9.3.1 INCREASING ADOPTION OF DIGITAL PATHOLOGY SOLUTIONS IN HOSPITALS TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 54 HOSPITAL DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS
                    TABLE 55 GLOBAL MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 56 DIGITAL PATHOLOGY SCANNERS MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 57 DIGITAL PATHOLOGY SCANNERS MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY REGION, 2019–2026 (UNITS)
    9.4 ACADEMIC & RESEARCH INSTITUTES
           9.4.1 FUNDING INVESTMENTS AND INITIATIVES TO BOOST THE GROWTH OF THIS END-USER SEGMENT IN THE GLOBAL MARKET
                    TABLE 58 GLOBAL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 59 DIGITAL PATHOLOGY SCANNERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 60 DIGITAL PATHOLOGY SCANNERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (UNITS)

10 DIGITAL PATHOLOGY MARKET, BY REGION (Page No. - 117)
     10.1 INTRODUCTION
             TABLE 61 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 31 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT
             TABLE 62 NORTH AMERICA: MARKET, BY COUNTRY,  2019–2026 (USD MILLION)
             TABLE 63 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 64 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 65 NORTH AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 66 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 67 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 68 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 69 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 70 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
             TABLE 71 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 72 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 73 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
             10.2.1 US
                        10.2.1.1 Favorable reimbursement scenario for digital pathology in the US to drive the adoption of digital pathology solutions
                                     TABLE 74 US: CANCER INCIDENCE RATE, 2020
                                     TABLE 75 US: DIGITAL PATHOLOGY CONFERENCES
                                     TABLE 76 US: KEY MACROINDICATORS
                                     TABLE 77 US: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 78 US: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 79 US: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 80 US: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 81 US: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 82 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 83 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Cancer awareness initiatives by the government to drive the market growth in Canada
                                     TABLE 84 CANADA: CANCER INCIDENCE RATE, 2020
                                     TABLE 85 CANADA: DIGITAL PATHOLOGY INITIATIVES AND FUNDING
                                     TABLE 86 CANADA: KEY MACROINDICATORS
                                     TABLE 87 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 88 CANADA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 89 CANADA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 90 CANADA: DIGITAL PATHOLOGY STANDLONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 91 CANADA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 92 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 93 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.3 EUROPE
             TABLE 94 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 95 EUROPE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 96 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 97 EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 98 EUROPE: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 99 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 100 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 101 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 102 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
             TABLE 103 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 104 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 105 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
             10.3.1 UK
                        10.3.1.1 The UK is the largest market for digital pathology in Europe owing to rising government funding & initiatives
                                     TABLE 106 CONFERENCES/COURSES HELD IN THE UK
                                     TABLE 107 UK: KEY MACROINDICATORS
                                     TABLE 108 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 109 UK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 110 UK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 111 UK: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 112 UK: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 113 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 114 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 High healthcare expenditure and supportive health insurance in Germany to drive the adoption of digital pathology solutions
                                     TABLE 115 GERMANY: CANCER INCIDENCE RATE, 2020
                                     TABLE 116 GERMANY: KEY MACROINDICATORS
                                     TABLE 117 GERMANY: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 118 GERMANY: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 119 GERMANY: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 120 GERMANY: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 121 GERMANY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 122 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 123 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.3 SWEDEN
                        10.3.3.1 Increasing government initiatives for the deployment of digital pathology solutions to drive the market growth in Sweden
                                     TABLE 124 SWEDEN: CANCER INCIDENCE RATE, 2020
                                     TABLE 125 SWEDEN: KEY MACROINDICATORS
                                     TABLE 126 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026(USD MILLION)
                                     TABLE 127 SWEDEN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 128 SWEDEN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 129 SWEDEN: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 130 SWEDEN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 131 SWEDEN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 132 SWEDEN: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.4 DENMARK
                        10.3.4.1 High prevalence of cancer to support the market growth in Denmark
                                     FIGURE 32 DENMARK: CANCER PREVALENCE, 2012–2020
                                     TABLE 133 DENMARK: CANCER INCIDENCE RATE, 2020
                                     TABLE 134 DENMARK: KEY MACROINDICATORS
                                     TABLE 135 DENMARK: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 136 DENMARK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 137 DENMARK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 138 DENMARK: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 139 DENMARK: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 140 DENMARK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 141 DENMARK: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.5 FRANCE
                        10.3.5.1 Increasing government funding and favorable insurance system are the major factors responsible for the rising adoption of digital pathology solutions in France
                                     TABLE 142 FRANCE: CANCER INCIDENCE RATE, 2020
                                     TABLE 143 FRANCE: KEY MACROINDICATORS
                                     TABLE 144 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 145 FRANCE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 146 FRANCE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 147 FRANCE: DIGITAL PATHOLOGY STANDLONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 148 FRANCE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 149 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 150 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE (ROE)
                        TABLE 151 ROE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 152 ROE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 153 ROE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 154 ROE: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 155 ROE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 156 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 157 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC (APAC)
             TABLE 158 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 159 ASIA PACIFIC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 160 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 161 ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 162 ASIA PACIFIC: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 163 ASIA PACIFIC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 164 ASIA PACIFIC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 165 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 166 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
             TABLE 167 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 168 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 169 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
             10.4.1 CHINA
                        10.4.1.1 Favorable initiatives by the government for the adoption of telepathology in China
                                     TABLE 170 CHINA: CANCER INCIDENCE RATE, 2020
                                     TABLE 171 CHINA: KEY MACROINDICATORS
                                     TABLE 172 CHINA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 173 CHINA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 174 CHINA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 175 CHINA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 176 CHINA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 177 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 178 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Universal healthcare reimbursement is driving the adoption of digital pathology solutions in Japan
                                     TABLE 179 JAPAN: CANCER INCIDENCE RATE, 2020
                                     TABLE 180 JAPAN: KEY MACROINDICATORS
                                     TABLE 181 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 182 JAPAN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 183 JAPAN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 184 JAPAN: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 185 JAPAN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 186 JAPAN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 187 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Growing number of cancer cases in India to drive market growth
                                     TABLE 188 INDIA: CANCER INCIDENCE RATE, 2020
                                     TABLE 189 INDIA: KEY MACROINDICATORS
                                     TABLE 190 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 191 INDIA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 192 INDIA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 193 INDIA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 194 INDIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 195 INDIA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 196 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC (ROAPAC)
                        TABLE 197 ROAPAC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 198 ROAPAC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 199 ROAPAC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 200 ROAPAC: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 201 ROAPAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 202 ROAPAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 203 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             TABLE 204 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
             TABLE 205 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
             TABLE 206 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
             TABLE 207 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 208 LATIN AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 209 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 210 LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 211 LATIN AMERICA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 212 LATIN AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 213 LATIN AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 214 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION 2019–2026 (USD MILLION)
             TABLE 215 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
             TABLE 216 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 217 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 218 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
             10.5.1 BRAZIL
                        10.5.1.1 Growing geriatric population and the subsequent increase in age-related disorders to drive the adoption of digital pathology solutions in Brazil
                                     TABLE 219 BRAZIL: CANCER INCIDENCE RATE, 2020
                                     TABLE 220 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 221 BRAZIL: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 222 BRAZIL: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 223 BRAZIL: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 224 BRAZIL: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 225 BRAZIL: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 226 BRAZIL: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Rising burden of infectious diseases to drive the uptake of digital pathology in Mexico
                                     TABLE 227 MEXICO: CANCER INCIDENCE RATE, 2020
                                     TABLE 228 MEXICO: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 229 MEXICO: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 230 MEXICO: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 231 MEXICO: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 232 MEXICO: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 233 MEXICO: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 234 MEXICO: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA (ROLATAM)
                        TABLE 235 ROLATAM: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 236 ROLATAM: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 237 ROLATAM: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 238 ROLATAM: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 239 ROLATAM: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 240 ROLATAM: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 241 ROLATAM: MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 INFRASTRUCTURAL DEVELOPMENTS IN THE REGION TO BOOST THE ADOPTION OF TECHNOLOGICALLY ADVANCED PATHOLOGY SOLUTIONS
                        TABLE 242 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                        TABLE 243 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 244 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 245 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 246 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 247 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 248 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 249 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 250 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
                        TABLE 251 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
                        TABLE 252 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
                        TABLE 253 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)

11 COMPETITIVE LANDSCAPE (Page No. - 196)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN
             FIGURE 33 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE DIGITAL PATHOLOGY MARKET
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN THE GLOBAL MARKET
     11.4 COMPETITIVE BENCHMARKING
             TABLE 254 FOOTPRINT OF COMPANIES IN THE GLOBAL MARKET
             TABLE 255 PRODUCT: COMPANY FOOTPRINT (25 COMPANIES)
             TABLE 256 END USER: COMPANY FOOTPRINT (25 COMPANIES)
             TABLE 257 REGION: COMPANY FOOTPRINT (26 COMPANIES)
     11.5 COMPETITIVE LEADERSHIP MAPPING
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 35 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 DYNAMIC COMPANIES
             11.6.3 STARTING BLOCKS
             11.6.4 RESPONSIVE COMPANIES
                        FIGURE 36 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020)
     11.7 MARKET SHARE ANALYSIS
             FIGURE 37 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     11.8 COMPETITIVE SCENARIO
             11.8.1 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 258 KEY PRODUCT LAUNCHES AND APPROVALS
             11.8.2 DEALS
                        TABLE 259 KEY DEALS

12 COMPANY PROFILES (Page No. - 211)
(Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
     12.1 KEY PLAYERS
             12.1.1 LEICA BIOSYSTEMS
                        TABLE 260 LEICA BIOSYSTEMS: BUSINESS OVERVIEW
                        FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.2 KONINKLIJKE PHILIPS N.V.
                        TABLE 261 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
                        FIGURE 39 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2020)
             12.1.3 HAMAMATSU PHOTONICS
                        TABLE 262 HAMAMATSU PHOTONICS: BUSINESS OVERVIEW
                        FIGURE 40 HAMAMATSU PHOTONICS: COMPANY SNAPSHOT (2020)
             12.1.4 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 263 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
             12.1.5 SECTRA AB
                        TABLE 264 SECTRA AB: BUSINESS OVERVIEW
                        FIGURE 42 SECTRA AB: COMPANY SNAPSHOT (2020)
             12.1.6 AKOYA BIOSCIENCES
                        TABLE 265 AKOYA BIOSCIENCES: BUSINESS OVERVIEW
                        FIGURE 43 AKOYA BIOSCIENCES: COMPANY SNAPSHOT (2020)
             12.1.7 3DHISTECH
                        TABLE 266 3DHISTECH: BUSINESS OVERVIEW
             12.1.8 APOLLO ENTERPRISE IMAGING CORP.
                        TABLE 267 APOLLO ENTERPRISE IMAGING CORP.: BUSINESS OVERVIEW
             12.1.9 XIFIN, INC.
                        TABLE 268 XIFIN, INC.: BUSINESS OVERVIEW
             12.1.10 HURON DIGITAL PATHOLOGY
                        TABLE 269 HURON DIGITAL PATHOLOGY: BUSINESS OVERVIEW
             12.1.11 VISIOPHARM
                        TABLE 270 VISIOPHARM: BUSINESS OVERVIEW
             12.1.12 CORISTA
                        TABLE 271 CORISTA: BUSINESS OVERVIEW
             12.1.13 INDICA LABS
                        TABLE 272 INDICA LABS: BUSINESS OVERVIEW
             12.1.14 OBJECTIVE PATHOLOGY SERVICES
                        TABLE 273 OBJECTIVE PATHOLOGY SERVICES: BUSINESS OVERVIEW
             12.1.15 OPTRASCAN, INC.
                        TABLE 274 OPTRASCAN, INC.: BUSINESS OVERVIEW
             12.1.16 GLENCOE SOFTWARE, INC.
                        TABLE 275 GLENCOE SOFTWARE, INC.: BUSINESS OVERVIEW
             12.1.17 AIFORIA TECHNOLOGIES OY
                        TABLE 276 AIFORIA TECHNOLOGIES OY: BUSINESS OVERVIEW
             12.1.18 PAIGE
                        TABLE 277 PAIGE: BUSINESS OVERVIEW
             12.1.19 INSPIRATA, INC.
                        TABLE 278 INSPIRATA, INC.: BUSINESS OVERVIEW
             12.1.20 PROSCIA, INC.
                        TABLE 279 PROSCIA, INC.: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS
             12.2.1 PATHAI
             12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
             12.2.3 MIKROSCAN TECHNOLOGIES, INC.
             12.2.4 MOTIC DIGITAL PATHOLOGY
             12.2.5 KANTERON SYSTEMS
*Details on Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 261)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Digital Pathology market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the Digital Pathology market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

A breakdown of the primary respondents is provided below:

Digital Pathology Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the Digital Pathology market was arrived at after data triangulation from two different approaches, as mentioned below.

Approach to calculate the revenue of different players in the Digital Pathology market. The size of the global Digital Pathology market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global Digital Pathology market was derived.

Approach to derive the market size and estimate market growth

The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Data Triangulation

After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Objectives of the Study

  • To define, describe, and forecast the Digital Pathology market based on product, type, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall Digital Pathology market
  • To analyze the opportunities in the market for stakeholders and provide details of
  • the competitive landscape for market leaders
  • To profile the key players in the market and comprehensively analyze their market shares and core competencies
  • To forecast the size of the market segments with respect to four main regions, namely,
  • North America, the Asia Pacific, Europe, Latin America, and Middle East & Africa.
  • To track and analyze competitive developments such as new product launches, agreements, collaborations, and expansions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific digital pathology market into South Korea, Australia, New Zealand, and other countries
  • Further breakdown of the Rest of Europe digital pathology market into Italy, Spain, Belgium, Russia, the Netherlands, Switzerland, and other countries
  • Further breakdown of the Rest of Latin America digital pathology market into Argentina, Chile, Peru, Colombia, and Cuba.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
HIT 2608
Published ON
Mar, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Digital Pathology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback